Browse > Article
http://dx.doi.org/10.5487/TR.2019.35.4.403

Theracurmin (Highly Bioavailable Curcumin) Prevents High Fat Diet-Induced Hepatic Steatosis Development in Mice  

Yang, Jin Won (College of Pharmacy, Woosuk University)
Yeo, Hee Kyung (HANDOK Inc.)
Yun, Jee Hye (HANDOK Inc.)
Lee, Jung Un (ChemOn Inc.)
Publication Information
Toxicological Research / v.35, no.4, 2019 , pp. 403-410 More about this Journal
Abstract
Curcumin, a hydrophobic polyphenol isolated from the Curcuma longa L. plant, has many pharmacological properties, including antioxidant, anti-inflammatory, and chemo-preventive activities. Curcumin has been shown to have potential in preventing nonalcoholic fatty liver disease (NAFLD). However, the low bioavailability of curcumin has proven to be a major limiting factor in its clinical adoption. Theracurmin, a highly bioavailable curcumin that utilizes micronized technology showed improved biological absorbability in vivo. The aim of this study was to investigate the role of theracurmin in modulating hepatic lipid metabolism in vivo. A fatty liver mouse model was produced by feeding mice a high fat diet (HFD; 60% fat) for 12 weeks. We found that treatment for 12 weeks with theracurmin significantly lowered plasma triacylglycerol (TG) levels and reduced HFD-induced liver fat accumulation. Theracurmin treatment lowered hepatic TG and total cholesterol (T-CHO) levels in HFD-fed mice compared to controls. In addition, theracurmin administration significantly reduced lipid peroxidation and cellular damage caused by reactive oxygen species in HFD-fed mice. Overall, these results suggest that theracurmin has the ability to control lipid metabolism and can potentially serve as an effective therapeutic remedy for the prevention of fatty liver.
Keywords
Theracurmin; Curcumin; Nonalcoholic fatty liver disease (NAFLD); High fat diet (HFD); Fatty liver; Steatosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Browning, J.D. and Horton, J.D. (2004) Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest., 114, 147-152.   DOI
2 Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M. and Sanyal, A.J. (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat. Med., 24, 908-922.   DOI
3 Birkenfeld, A.L. and Shulman, G.I. (2014) Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology, 59, 713-723.   DOI
4 Marra, F., Gastaldelli, A., Svegliati Baroni, G., Tell, G. and Tiribelli, C. (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med., 14, 72-81.   DOI
5 Kotronen, A. and Yki-Jarvinen, H. (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 28, 27-38.   DOI
6 Rinella, M.E. (2015) Nonalcoholic fatty liver disease: a systematic review. JAMA, 313, 2263-2273.   DOI
7 Sunagawa, Y., Hirano, S., Katanasaka, Y., Miyazaki, Y., Funamoto, M., Okamura, N., Hojo, Y., Suzuki, H., Doi, O., Yokoji, T., Morimoto, E., Takahashi, T., Ozawa, H., Imaizumi, A., Ueno, M., Kakeya, H., Shimatsu, A., Wada, H., Hasegawa, K. and Morimoto, T. (2015) Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study. J. Nutr. Sci. Vitaminol., 61, 37-44.   DOI
8 Maria, M., Eleni, P., George, V., Eftychia, T. and Constantinos, G. (2018) Effects of curcumin consumption on human chronic diseases: A narrative review of the most recent clinical data. Phytother. Res., 32, 957-975.   DOI
9 Ohno, M., Nishida, A., Sugitani, Y., Nishino, K., Inatomi, O., Sugimoto, M., Kawahara, M. and Andoh, A. (2017) Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells. PLoS ONE, 12, e0185999.   DOI
10 Farzaei, M.H., Zobeiri, M., Parvizi, F., El-Senduny, F.F., Marmouzi, I., Coy-Barrera, E., Naseri, R., Nabavi, S.M., Rahimi, R. and Abdollahi, M. (2018) Curcumin in liver diseases: a systematic review of the cellular mechanisms of oxidative stress and clinical perspective. Nutrients, 10, E855.   DOI
11 Imaizumi, A. (2015) Highly bioavailable curcumin (Theracurmin): its development and clinical application. Pharma-Nutrition, 3, 123-130.   DOI
12 Ding, L., Li, J., Song, B., Xiao, X., Zhang, B., Qi, M., Huang, W., Yang, L. and Wang, Z. (2016) Curcumin rescues high fat diet-induced obesity and insulin sensitivity in mice through regulating SREBP pathway. Toxicol. Appl. Pharmacol., 304, 99-109.   DOI
13 Cichoz-Lach, H. and Michalak, A. (2014) Oxidative stress as a crucial factor in liver diseases. World J. Gastroenterol., 20, 8082-8091.   DOI
14 Shao, W., Yu, Z., Chiang, Y., Yang, Y., Chai, T., Foltz, W., Lu, H., Fantus, I.G. and Jin, T. (2012) Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS ONE, 7, e28784.   DOI
15 Sasaki, H., Sunagawa, Y., Takahashi, K., Imaizumi, A., Fukuda, H., Hashimoto, T., Wada, H., Katanasaka, Y., Kakeya, H., Fujita, M., Hasegawa, K. and Morimoto, T. (2011) Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull., 34, 660-665.   DOI
16 Cuomo, J., Appendino, G., Dern, A.S., Schneider, E., McKinnon, T.P., Brown, M.J., Togni, S. and Dixon, B.M. (2011) Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J. Nat. Prod., 74, 664-669.   DOI
17 Gota, V.S., Maru, G.B., Soni, T.G., Gandhi, T.R., Kochar, N. and Agarwal, M.G. (2010) Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food Chem., 58, 2095-2099.   DOI
18 Sunagawa, Y., Wada, H., Suzuki, H., Sasaki, H., Imaizumi, A., Fukuda, H., Hashimoto, T., Katanasaka, Y., Shimatsu, A., Kimura, T., Kakeya, H., Fujita, M., Hasegawa, K. and Morimoto, T. (2012) A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rats. Biol. Pharm. Bull., 35, 139-144.   DOI
19 Liu, Y., Cheng, F., Luo, Y., Zhan, Z., Hu, P., Ren, H., Tang, H. and Peng, M. (2017) PEGylated curcumin derivative attenuates hepatic steatosis via CREB/PPAR-gamma/CD36 pathway. BioMed Res. Int., 2017, 8234507.
20 Oner-Iyidogan, Y., Kocak, H., Seyidhanoglu, M., Gurdol, F., Gulcubuk, A., Yildirim, F., Cevik, A. and Uysal, M. (2013) Curcumin prevents liver fat accumulation and serum fetuin-A increase in rats fed a high-fat diet. J. Physiol. Biochem., 69, 677-686.   DOI
21 Greenberg, A.S., Coleman, R.A., Kraemer, F.B., McManaman, J.L., Obin, M.S., Puri, V., Yan, Q.W., Miyoshi, H. and Mashek, D.G. (2011) The role of lipid droplets in metabolic disease in rodents and humans. J. Clin. Invest., 121, 2102-2110.   DOI
22 Ioannou, G.N. (2016) The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol. Metab., 27, 84-95.   DOI
23 Rolo, A.P., Teodoro, J.S. and Palmeira, C.M. (2012) Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med., 52, 59-69.   DOI
24 Walenbergh, S.M. and Shiri-Sverdlov, R. (2015) Cholesterol is a significant risk factor for non-alcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol., 9, 1343-1346.   DOI
25 Shimano, H. and Sato, R. (2017) SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat. Rev. Endocrinol., 13, 710-730.   DOI
26 Yang, J.W., Kim, H.S., Im, J.H., Kim, J.W., Jun, D.W., Lim, S.C., Lee, K., Choi, J.M., Kim, S.K. and Kang, K.W. (2016) GPR119: a promising target for nonalcoholic fatty liver disease. FASEB J., 30, 324-335.   DOI
27 Moore, K.J., Rayner, K.J., Suarez, Y. and Fernandez-Hernando, C. (2011) The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu. Rev. Nutr., 31, 49-63.   DOI
28 Tariq, Z., Green, C.J. and Hodson, L. (2014) Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? Liver Int., 34, e180-e190.   DOI
29 Spahis, S., Delvin, E., Borys, J.M. and Levy, E. (2017) oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid. Redox Signal., 26, 519-541.   DOI
30 Negre-Salvayre, A., Auge, N., Ayala, V., Basaga, H., Boada, J., Brenke, R., Chapple, S., Cohen, G., Feher, J., Grune, T., Lengyel, G., Mann, G.E., Pamplona, R., Poli, G., Portero-Otin, M., Riahi, Y., Salvayre, R., Sasson, S., Serrano, J., Shamni, O., Siems, W., Siow, R.C.M., Wiswedel, I., Zarkovic, K. and Zarkovic, N. (2010) Pathological aspects of lipid peroxidation. Free Radic. Res., 44, 1125-1171.   DOI
31 He, H.-J., Wang, G.-Y., Gao, Y., Ling, W.-H., Yu, Z.-W. and Jin, T.-R. (2012) Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice. World J. Diabetes, 3, 94.   DOI
32 Wei, Q.Y., Chen, W.F., Zhou, B., Yang, L. and Liu, Z.L. (2006) Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim. Biophys. Acta, 1760, 70-77.   DOI
33 Scapagnini, G., Vasto, S., Abraham, N.G., Caruso, C., Zella, D. and Fabio, G. (2011) Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol. Neurobiol., 44, 192-201.   DOI
34 Yang, C., Zhang, X., Fan, H. and Liu, Y. (2009) Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res., 1282, 133-141.   DOI